| The Institute of Cancer Research: Royal Cancer Hospital Patent applications |
| Patent application number | Title | Published |
|---|
| 20110269808 | COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES - The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)-1-[4-( | 11-03-2011 |
| 20110144080 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS - The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R | 06-16-2011 |
| 20100130496 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE - The invention provides a pyrimidine compound of formula (I): | 05-27-2010 |
| 20100130464 | PHARMACEUTICAL COMPOUNDS - The invention provides compounds of the formula (I) having ROCK kinase and/or protein kinase p70S6K inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR | 05-27-2010 |
| 20100022564 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS - The invention provides a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR | 01-28-2010 |
| 20100016340 | PHARMACEUTICAL COMPOUNDS - The invention provides compounds of the formula (I): | 01-21-2010 |
| 20090253718 | Pharmaceutical Compounds - The invention provides a compound having the formula (I): | 10-08-2009 |
| 20090099213 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors - The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase B, the compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR | 04-16-2009 |
| 20080241825 | Materials and Methods for Treatment of Cancer - Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumours which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed. | 10-02-2008 |
